Description
Glioblastoma (GBM) is the most lethal primary brain tumor in adults with a less than 5% chance of survival beyond 5 years. With few effective therapies beyond the standard of care, there are often treatment resistant recurrences seen in most patients. STAT5 is a protein that has shown to be upregulated in highly invasive and treatment resistant GBM. Elucidating the role of STAT5 in GBM could reveal a node of therapeutic vulnerability in primary and recurrent GBM.
Copyright Statement
Reuse Permissions
Details
Title
- SRC Dependent EGFRvIII-STAT5 Activation Drives Resistance of Glioblastoma Cells
Contributors
- Inforzato, Hannah (Author)
- Plaisier, Christopher (Thesis director)
- Tran, Nhan (Committee member)
- Blomquist, Mylan (Committee member)
- Barrett, The Honors College (Contributor)
- School of Life Sciences (Contributor)
- Department of Psychology (Contributor)
Date Created
The date the item was original created (prior to any relationship with the ASU Digital Repositories.)
2022-05
Subjects
Resource Type
Collections this item is in